Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Stopped early · Phase 2
Conditions studied: Multiple Myeloma
In brief
Current therapies for Multiple Myeloma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Multiple Myeloma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Multiple Myeloma.
Key facts
- Study ID
- NCT00003511
- Run by
- Burzynski Research Institute
- People needed
- 5
- Starts
- 1996-04-04
- Expected to finish
- 1999-10-21
- Last updated by the study team
- 2021-06-09
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Burzynski Clinic — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.